FibroGen, fresh off data manipulation scandal, touts win in cancer patients without revealing data

FibroGen’s lead drug has cleared another mid-stage study. Or at least the biotech claims it has.

FibroGen, a 28-year-old company whose stock collapsed this past year after it revealed data it had submitted to the FDA was manipulated, said Wednesday that roxadustat, its pill for anemia, successfully treated cancer patients who suffered anemia as a side effect of chemotherapy.